The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis

Summary

Variant cytochrome P450 (CYP) 2C9 genotypes are associated with low maintenance dose requirement of warfarin therapy and increased risk of major bleeding events. The objective of the present study was to evaluate the potential clinical and economic outcomes of using CYP2C9 genotype data to guide the management of anticoagulation therapy and to identify influential factors affecting the cost-effectiveness of this treatment scheme. A decision tree was designed to simulate, over 12 months, the clinical and economic outcomes of patients newly started on warfarin associated with two alternatives: (1) no genotyping (non-genotyped group) and (2) CYP2C9 genotyping prior to initiation of warfarin therapy (genotyped group). Nongenotyped group patients would receive standard care of an anticoagulation clinic (AC). In the genotyped group, patients with at least one variant CYP2C9 allele would receive intensified anticoagulation service. Most of the clinical probabilities were derived from literature. The direct medical costs were estimated from the Diagnosis-Related Group charges and from literature. The total number of events and the direct medical cost per 100 patient-years in the genotyped and non-genotyped groups were 9.58 and USD155,700, and, 10.48 and USD 150,500, respectively. The marginal cost per additional major bleeding averted in the genotyped group was USD 5,778. The model was sensitive to the variation of the cost and reduction of bleeding rate in the intensified anticoagulation service. In conclusion, the pharmacogenetics-oriented management of warfarin therapy is potentially more effective in preventing bleeding with a marginal cost. The cost-effectiveness of this treatment scheme depends on the relative cost and effectiveness of a pharmacogenetics-oriented intensified anticoagulation service comparing to the standard AC care.

Keywords

Warfarin - CYP2C9 - cost-effectiveness

• References

• 1 Hirsch H, Dalen JE, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
• 2 Loebstein R, Yonath H, Peleg D. et al. Interindividual variability in sensitivity to warfarin – nature or nuture?. Clin Pharmacol Ther 2001; 70: 159-64.
• 3 James AH, Britt RP, Raskino CL. et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-6.
• 4 Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinetics 1986; 11: 483-504.
• 5 Chan E, McLachlan A, O’Reilly R. et al. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokineticpharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-94.
• 6 Haber LT, Maier A, Gentry PR. et al. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg Toxicol Pharmacol 2002; 35: 177-97.
• 7 Takahashi H, Kashima T, Nomizo Y. et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP 2C9 and CYPC19 genotypes. Clin pharmacol Ther 1998; 63: 519-28.
• 8 Scordo MG, Pengo V, Spina E. et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-10.
• 9 Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.imm.ki.se/CYPalleles/ (assessed on 5 March 04).
• 10 Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
• 11 Xie HG, Prasad HC, Kim RB. et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
• 12 Aithal GP, Day CP, Kesteven PJ. et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
• 13 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
• 14 Higashi MK, Veenstra DL. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287 (13) 1690-8.
• 15 Ogg MS, Brennan B, Meade T. et al. CYP2C9*3 allelic variant and bleeding complications. Lancet 1999; 354: 1124.
• 16 Gage BF, Eby C, Milligan PE. et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
• 17 Fihn SD, McDonell M, Martin D. et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-20.
• 18 You JHS, Chan FWH, Wong RSM. et al. Costeffectiveness of two models of management for patients on chronic warfarin therapy – A Markov model analysis. Thromb Haemost 2003; 90: 1106-11.
• 19 Tabrizi AR, Zehnbauer BA, Borecki IB. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002; 194: 267-73.
• 20 Scordo MG, Aklillu E, Yasar U. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
• 21 Freeman BD, Zehnbauer BA, McGrath S. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128: 281-5.
• 22 Takahashi H, Wilkinson GR, Caraco Y. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-63.
• 23 Margaglione M, Colaizzo D, D’Andrea G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
• 24 Yasar U, Eliasson E, Dahl ML. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31.
• 25 Aynacioglu AS, Brockmöller J, Bauer S. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15.
• 26 Garcia EMartin, Martinez C, Ladero JM. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9.
• 27 Holm T, Lassen JF, Husted SE. et al. A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med 2002; 252: 322-31.
• 28 Poli D, Antonucci E, Lombardi A. et al. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagul Fibrinolysis 2003; 14: 269-75.
• 29 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
• 30 Errichette AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch Intern Med 1984; 144: 1966-8.
• 31 Charney R, Leddomado E, Rose DN. et al. Anticoagulation clinics and the monitoring of anticoagulation therapy. Int J Cardiol 1988; 18: 197-206.
• 32 Searbrook GR, Karp D, Schmitt DD. et al. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surg 1990; 160: 501-5.
• 33 Cannegieter SC, Rosendaal FR, Wintzen AR. et al. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
• 34 Cortelazzo S, Finazzi G, Viero P. et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69: 316-20.
• 35 Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
• 36 Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized clinical trial. Ann Intern Med 2000; 133: 687-95.
• 37 Centers for Medicare & Medicaid Services. http://cms.hhs.gov/statistics/medpar/default.asp (assessed on June 1, 2003)
• 38 Menzin J, Boulanger L, Hauch O. et al. The cost of warfarin monitoring in anticoagulation clinics: A multi-site managed case study. Value in Health 2002; 05: 165.
• 39 Sullivan-Klose TH, Ghanayem BI, Bell DA. et al. The role of the CYP 2C9-Leu³⁵⁹ allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 06: 341-9.
• 40 Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP 2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 07: 405-9.
• 41 Wang SL, Huang J, Lai MD. et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 05: 37-42.
• 42 Yoon YR, Shon JH, Kim MK. et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80.
• 43 Ensom MHH, Chang TKH, Patel P. Pharmacogenetics: The therapeutic drug monitoring of the Future?. Clin Pharmacokinet 2001; 40: 783-802.
• 44 Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998; 63: 11-6.
• 45 Baselga J, Norton L, Albanell J. et al. Recombinant humanized anti-HER2 antibody (HERCEPTIN) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
• 46 Farlow MR, Lahiri DK, Poirier J. et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci 1996; 802: 101-10.
• 47 Palareti G, Manotti C, DAngelo A. et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78: 1438-43.
• 48 Hiratsuka M, Agatsuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab 1999; 68: 357-62.
• 49 Weinstein MC, Siegel JE, Gold MR. et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8.
• 50 Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 1992; 12: 239-49.
• 51 Fryback DG, Dasbach EJ, Klein R. et al. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.
• 52 Thomson R, Parkin D, Eccles M. et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. BMJ 2000; 355: 956-62.